Dr Reddy’s Launches Low-Cost Semaglutide Generic ‘Obeda’ in India’s Booming GLP-1 Market
Dr. Reddy’s Laboratories has entered the fast-growing GLP-1 therapy segment with the launch of its semaglutide generic, Obeda, for Type…
Dr. Reddy’s Laboratories has entered the fast-growing GLP-1 therapy segment with the launch of its semaglutide generic, Obeda, for Type…
The patent for semaglutide the key ingredient in Ozempic and Wegovy developed by Novo Nordisk is set to expire in…
India’s Dr Reddy’s Laboratories is preparing to introduce a significantly lower-priced generic version of blockbuster weight-loss drug Wegovy, currently sold…
Danish pharmaceutical giant Novo Nordisk (NOVOb.CO) is preparing to roll out its diabetes medication Ozempic in India within the next…
Eli Lilly, the U.S.-based pharmaceutical giant, plans to introduce its obesity and diabetes drug Tirzepatide (marketed as Mounjaro) in India…
Semaglutide: A Dual Benefit for Heart Health and Weight Loss, but Potential Gut Issues Ahead semaglutide has emerged as a…
Semaglutide, a medication initially developed for the treatment of type 2 diabetes and obesity, is now showing promising results in…